Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target

@article{Zalewski2005RoleOL,
  title={Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target},
  author={Andrew A. Zalewski and Colin H. Macphee},
  journal={Arteriosclerosis, Thrombosis, and Vascular Biology},
  year={2005},
  volume={25},
  pages={923-931}
}
The development of atherosclerotic vascular disease is invariably linked to the formation of bioactive lipid mediators and accompanying vascular inflammation. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that is produced by inflammatory cells, co-travels with circulating low-density lipoprotein (LDL), and hydrolyzes oxidized phospholipids in LDL. Its biological role has been controversial with initial reports purporting atheroprotective effects of Lp-PLA2 thought to be a… 

Figures and Tables from this paper

Lipoprotein-associated phospholipase A2 and atherosclerosis

Persistent and sustained macrophage apoptosis appears to play a major role in the resulting local inflammatory response in part by effects elicited by Lp-PLA2, which may be an important link between lipid homeostasis and the vascular inflammatory response.

Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).

Plasma levels of Lp-PLA2 are increased in various types of hyperlipidemias, while hypolipidemic drugs reduce plasma Lp -PLA2 activity and mass along with the improvement of plasma lipid profile and darapladib prevents the expansion of necrotic core volume.

Lipoprotein-associated phospholipase A2 as a target of therapy

Lp-PLA2 is intimately associated with several aspects of human atherogenesis, and various lipid-lowering therapies, such as statins, have been studied in terms of its ability to lower the large macrophage-mediated upregulation of Lp- PLA2 within advanced plaques.

Lipoprotein-associated phospholipase A2: novel biomarker and causal mediator of atherosclerosis?

  • N. Jenny
  • Biology
    Arteriosclerosis, thrombosis, and vascular biology
  • 2006
Inflammation is clearly recognized as a central component in the development and progression of cardiovascular disease (CVD). What is not clear, however, is how to best identify and monitor

Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.

Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a review

The evaluation of the distribution of Lp-PLA2 in the lipid fractions emphasized the dual role of the enzyme in the inflammatory process, since the HDL-Lp- PLA2 enzyme contributes to the reduction of atherosclerosis, while LDL- lysophospholipids stimulates this process.

Pathophysiological Aspects of Lipoprotein-Associated Phospholipase A 2 : A Brief Overview

Darapladib (a product of GlaxoSmithKline) is now considered as an important therapeutic agent to inhibit Lp-PLA2 activity, and it shows important association with markers of cardiovascular disorder.

Lp-PLA2: a new kid on the block.

Unanswered questions still exist with respect to this enzyme and its biologic role in atherosclerosis, and addressing these questions will help clarify the clinical utility of measuring Lp-PLA2 in routine clinical practice in the context of other approaches for identifying high-risk patients.

Lp-PLA 2 : A New Kid on the Block

Lp-PLA2 is an intriguing marker of cardiovascular risk and may also be a marker of plaque activity/vulnerability and unanswered questions still exist with respect to this enzyme and its biologic role in atherosclerosis.

Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

...

References

SHOWING 1-10 OF 101 REFERENCES

Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions.

Macrophages in both human and rabbit atherosclerotic lesions express Lp-PLA(2), which could cleave any oxidatively modified phosphatidylcholine present in the lesion area, which could lead to antiatherogenic effects in the vessel wall.

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.

In addition to generating lysophosphatidylcholine, a known biologically active lipid, these results demonstrate that Lp-PLA2 is capable of generating oxidized non-esterified fatty acid moieties that are also bioactive, consistent with the proposal that L p- PLA2 has a predominantly pro-inflammatory role in atherogenesis.

Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.

It is suggested that PAF-AH in HDL protects against the production and activity of MM-LDL by facilitating hydrolysis of active oxidized phospholipid species to lysolipids, thereby destroying the biologically active lipids in MM- LDL.

Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.

Increased plasma NEFAs, PAF-AH mRNA and enzyme activities are associated with accelerated atherogenesis in these animal models.

Expression of G2A, a Receptor for Lysophosphatidylcholine, by Macrophages in Murine, Rabbit, and Human Atherosclerotic Plaques

Findings demonstrate that monocytes/macrophages abundantly express G2A and suggest that G 2A may play a role in the formation and progression of atherosclerotic lesions.

Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients

Results indicated that both novel mutants, InsA191 and I317N, impair function of the Lp-PLA2 gene.

Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

Recombinant PAF acetylhydrolase has the sub-strate specificity and lipoprotein association of the native enzyme, and blocks inflammation in vivo: it markedly decreases vascular leakage in pleurisy and paw oedema, suggesting that PAFacetylHydrolase might be a useful therapy for severe acute inflammation.

Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration.

Results indicate that lysophosphatidylcholine induces human coronary artery SMC migration at least in part through release of endogenous bFGF and this lyso-PC-induced migration can be further induced by PDGF-BB and ET-1 and can be inhibited by human AM and vitamin E.

Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study

The Rotterdam Study shows that Lp-PLA2 activity is an independent predictor of coronary heart disease and ischemic stroke in the general population and was present in both subjects with non-HDL cholesterol levels below the median and those withnon-HDl cholesterol levels above the median.
...